HRP20100619T1 - Derivat 2-aminobiciklo[3.1.0]heksan-2,6-dikarboksilnog estera - Google Patents
Derivat 2-aminobiciklo[3.1.0]heksan-2,6-dikarboksilnog estera Download PDFInfo
- Publication number
- HRP20100619T1 HRP20100619T1 HR20100619T HRP20100619T HRP20100619T1 HR P20100619 T1 HRP20100619 T1 HR P20100619T1 HR 20100619 T HR20100619 T HR 20100619T HR P20100619 T HRP20100619 T HR P20100619T HR P20100619 T1 HRP20100619 T1 HR P20100619T1
- Authority
- HR
- Croatia
- Prior art keywords
- hexane
- bicyclo
- hydrate
- amino
- pharmaceutically acceptable
- Prior art date
Links
- -1 hexane-2,6-dicarboxylic ester Chemical class 0.000 title claims abstract 29
- 150000003839 salts Chemical class 0.000 claims abstract 14
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 claims abstract 3
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims abstract 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims abstract 3
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims abstract 3
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims abstract 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims abstract 3
- 125000000217 alkyl group Chemical group 0.000 claims abstract 2
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 2
- 239000011737 fluorine Substances 0.000 claims abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 2
- 239000001257 hydrogen Substances 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000002740 Muscle Rigidity Diseases 0.000 claims 1
- 206010028570 Myelopathy Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000003925 brain function Effects 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C221/00—Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Detergent Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003181930 | 2003-06-26 | ||
JP2003373511 | 2003-10-31 | ||
JP2004128663 | 2004-04-23 | ||
PCT/JP2004/009398 WO2005000791A1 (ja) | 2003-06-26 | 2004-06-25 | 2-アミノ-ビシクロ[3.1.0]ヘキサン-2,6-ジカルボン酸エステル誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100619T1 true HRP20100619T1 (hr) | 2011-01-31 |
Family
ID=33556154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100619T HRP20100619T1 (hr) | 2003-06-26 | 2010-11-15 | Derivat 2-aminobiciklo[3.1.0]heksan-2,6-dikarboksilnog estera |
Country Status (21)
Country | Link |
---|---|
US (5) | US7960579B2 (de) |
EP (3) | EP2123630B1 (de) |
JP (1) | JP4792971B2 (de) |
KR (1) | KR101071507B1 (de) |
AT (1) | ATE487690T1 (de) |
AU (2) | AU2004252017B2 (de) |
BR (1) | BRPI0411823A (de) |
CA (1) | CA2530706C (de) |
CY (1) | CY1110997T1 (de) |
DE (1) | DE602004030007D1 (de) |
DK (2) | DK1637517T3 (de) |
ES (1) | ES2394175T3 (de) |
HK (1) | HK1095318A1 (de) |
HR (1) | HRP20100619T1 (de) |
MX (1) | MXPA05013740A (de) |
NO (1) | NO335004B1 (de) |
NZ (2) | NZ544131A (de) |
PL (1) | PL1637517T3 (de) |
PT (1) | PT1637517E (de) |
SI (1) | SI1637517T1 (de) |
WO (1) | WO2005000791A1 (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005000791A1 (ja) * | 2003-06-26 | 2005-01-06 | Taisho Pharmaceutical Co., Ltd. | 2-アミノ-ビシクロ[3.1.0]ヘキサン-2,6-ジカルボン酸エステル誘導体 |
TW201129700A (en) | 2009-11-18 | 2011-09-01 | Taisho Pharmaceutical Co Ltd | Method for producing optically active bicyclo [310] hexane derivative using oxygen |
WO2011061935A1 (ja) * | 2009-11-19 | 2011-05-26 | 大正製薬株式会社 | 3-アルコキシ-2-アミノ-6-フルオロビシクロ[3.1.0]ヘキサン-2,6-ジカルボン酸誘導体及びその中間体の製造方法 |
MX2013005623A (es) * | 2010-11-18 | 2013-07-05 | Lilly Co Eli | Compuestos de 3-benciloxi-biciclico [3.1.0] hexano 4-sustituidos como antagonistas de mglur 2/3. |
TWI520935B (zh) | 2010-11-18 | 2016-02-11 | 美國禮來大藥廠 | 作為mGluR2/3拮抗劑之4-經取代-3-苯基磺醯基甲基-雙環[3.1.0]己烷化合物 |
WO2013062680A1 (en) * | 2011-10-25 | 2013-05-02 | Braincells, Inc. | Novel compounds and compositions thereof for treating nervous system disorders |
AR089718A1 (es) | 2012-02-01 | 2014-09-10 | Lilly Co Eli | AGONISTAS DE mGlu2/3 |
JP5983713B2 (ja) * | 2013-11-29 | 2016-09-06 | 大正製薬株式会社 | 含フッ素アミノ酸のプロドラッグを含有する医薬 |
FR3026843B1 (fr) * | 2014-10-03 | 2016-11-18 | Univ Pierre Et Marie Curie (Paris 6) | Procede de caracterisation du mecanisme de fissuration d'un materiau a partir de sa surface de rupture |
HUE056046T2 (hu) | 2016-04-18 | 2022-01-28 | Taisho Pharmaceutical Co Ltd | Aminosav-származék prodrogja |
US11173145B2 (en) | 2017-01-17 | 2021-11-16 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
KR101877672B1 (ko) | 2017-04-03 | 2018-07-11 | 엘에스산전 주식회사 | Ad컨버터 |
US11046649B2 (en) | 2018-07-17 | 2021-06-29 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
US11501618B1 (en) * | 2018-10-19 | 2022-11-15 | Amazon Technologies, Inc. | Security device with user-configurable motion detection settings |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5661184A (en) | 1994-08-12 | 1997-08-26 | Eli Lilly And Company | Psychiatric agents |
GB9605429D0 (en) * | 1995-11-16 | 1996-05-15 | Lilly Co Eli | Excitatory amino acid receptor antagonists |
ZA983930B (en) | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
CN1247527C (zh) | 1998-08-31 | 2006-03-29 | 大正制药株式会社 | 6-氟双环[3.1.0]己烷衍生物 |
JP4194715B2 (ja) | 1998-08-31 | 2008-12-10 | 大正製薬株式会社 | 6−フルオロビシクロ[3.1.0]ヘキサン誘導体 |
CH694053A5 (de) * | 1998-09-03 | 2004-06-30 | Hoffmann La Roche | Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten. |
AU2001267854B2 (en) * | 2000-06-28 | 2005-12-01 | Taisho Pharmaceutical Co., Ltd. | Novel dicarboxylic acid derivatives |
EP1370519A1 (de) * | 2001-02-22 | 2003-12-17 | Eli Lilly And Company | Synthetische excitatorische aminosäuren |
CA2471642C (en) * | 2001-12-27 | 2011-05-24 | Taisho Pharmaceutical Co., Ltd. | 6-fluorobicyclo[3.1.0]hexane derivatives |
WO2005000790A1 (ja) | 2003-06-26 | 2005-01-06 | Taisho Pharmaceutical Co., Ltd. | 2-アミノビシクロ[3.1.0]ヘキサン-2,6-ジカルボン酸誘導体 |
JP2007063129A (ja) | 2003-06-26 | 2007-03-15 | Taisho Pharmaceut Co Ltd | 2−アミノ−3−アルコキシビシクロ[3.1.0]ヘキサン誘導体 |
WO2005000791A1 (ja) * | 2003-06-26 | 2005-01-06 | Taisho Pharmaceutical Co., Ltd. | 2-アミノ-ビシクロ[3.1.0]ヘキサン-2,6-ジカルボン酸エステル誘導体 |
-
2004
- 2004-06-25 WO PCT/JP2004/009398 patent/WO2005000791A1/ja active Application Filing
- 2004-06-25 DK DK04746867.3T patent/DK1637517T3/da active
- 2004-06-25 EP EP09166100A patent/EP2123630B1/de not_active Expired - Lifetime
- 2004-06-25 NZ NZ544131A patent/NZ544131A/xx not_active IP Right Cessation
- 2004-06-25 PL PL04746867T patent/PL1637517T3/pl unknown
- 2004-06-25 AU AU2004252017A patent/AU2004252017B2/en not_active Ceased
- 2004-06-25 CA CA2530706A patent/CA2530706C/en not_active Expired - Fee Related
- 2004-06-25 NZ NZ580554A patent/NZ580554A/en not_active IP Right Cessation
- 2004-06-25 US US10/562,018 patent/US7960579B2/en not_active Expired - Fee Related
- 2004-06-25 AT AT04746867T patent/ATE487690T1/de active
- 2004-06-25 PT PT04746867T patent/PT1637517E/pt unknown
- 2004-06-25 ES ES09166100T patent/ES2394175T3/es not_active Expired - Lifetime
- 2004-06-25 DE DE602004030007T patent/DE602004030007D1/de not_active Expired - Lifetime
- 2004-06-25 MX MXPA05013740A patent/MXPA05013740A/es active IP Right Grant
- 2004-06-25 BR BRPI0411823-5A patent/BRPI0411823A/pt not_active IP Right Cessation
- 2004-06-25 EP EP04746867A patent/EP1637517B1/de not_active Expired - Lifetime
- 2004-06-25 EP EP10181930.8A patent/EP2287147B1/de not_active Expired - Lifetime
- 2004-06-25 SI SI200431569T patent/SI1637517T1/sl unknown
- 2004-06-25 JP JP2005511127A patent/JP4792971B2/ja not_active Expired - Lifetime
- 2004-06-25 DK DK09166100.9T patent/DK2123630T3/da active
- 2004-06-25 KR KR1020057024818A patent/KR101071507B1/ko not_active IP Right Cessation
-
2006
- 2006-01-26 NO NO20060428A patent/NO335004B1/no not_active IP Right Cessation
-
2007
- 2007-01-25 HK HK07100898.6A patent/HK1095318A1/xx not_active IP Right Cessation
-
2009
- 2009-07-29 US US12/511,482 patent/US8039647B2/en not_active Expired - Fee Related
- 2009-09-15 AU AU2009217374A patent/AU2009217374B2/en not_active Ceased
-
2010
- 2010-07-30 US US12/847,392 patent/US8076502B2/en not_active Expired - Fee Related
- 2010-11-15 HR HR20100619T patent/HRP20100619T1/hr unknown
- 2010-12-17 CY CY20101101160T patent/CY1110997T1/el unknown
-
2011
- 2011-09-08 US US13/227,942 patent/US8350060B2/en not_active Expired - Fee Related
- 2011-10-07 US US13/269,242 patent/US8258133B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100619T1 (hr) | Derivat 2-aminobiciklo[3.1.0]heksan-2,6-dikarboksilnog estera | |
JP2018519329A5 (de) | ||
HRP20211282T1 (hr) | Oksisteroli i postupci njihovog korištenja | |
MX2009004801A (es) | Amidas de diazabicicloalcanos selectivas de subtipo de receptor nicotinico de acetilcolina. | |
HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
HRP20150982T1 (hr) | Novi modulatori sfingozin fosfat receptora | |
JP2015501783A5 (de) | ||
ES2560095T3 (es) | Amidas bicíclicas para mejorar las respuestas sinápticas glutamatérgicas | |
UA104869C2 (uk) | Фармацевтичні композиції, що містять ліганди рецептора дофаміну | |
HRP20180874T4 (hr) | Selektivni modulatori receptora sfingozin-1-fosfata i postupci kiralne sinteze | |
NZ590951A (en) | Cyclic nucleotide phosphodiesterases PDE10 inhibitors for treating neurological disorders | |
HRP20140195T1 (hr) | Supstituirani derivati triazolopiridazina | |
MX354423B (es) | Formulaciones de rasagilina de liberación prolongada y usos de las mismas. | |
ATE430741T1 (de) | Piperidinverbindungen und pharmazeutische zusammensetzungen, die diese enthalten | |
BR112014029478A8 (pt) | compostos, fármacos de aminoácido contendo flúor e uso destes | |
TW200745135A (en) | Therapeutic agents | |
WO2011149354A8 (en) | Mirnas involved in the blood brain barrier function | |
HRP20140326T1 (hr) | Derivat aromatiäśnog 6-äślanog prstena koji sadrži dušik i farmaceutsko sredstvo koje sadrži taj derivat | |
BRPI0419067A (pt) | método para aumento da cognição utilizando ziprasidona | |
HRP20160545T1 (hr) | Inhibitor fosfoinozitid 3-kinaze sa dijelom koji veže cink | |
IL202236A0 (en) | Prolinamide derivatives as nk3 antagonists | |
MY189740A (en) | Butylphthalide-telmisartan heterocomplex, preparation method and application thereof | |
JP2021504326A5 (de) | ||
HRP20230774T1 (hr) | Heteroaromatični modulatori nmda receptora i njihove upotrebe | |
HRP20150809T1 (hr) | Spojevi morfinana |